Poxel
Research integrated pharmaceutical company that develops products for metabolic diseases.
Launch date
Employees
Market cap
CAD43.9m
Enterprise valuation
CAD101m (Public information from Sep 2024)
Share price
€0.53 POXEL.PA
Company register number 510970817
Lyon Auvergne-Rhône-Alpes (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.0m | 74.0m | 26.6m | 6.8m | 13.4m | <1m | 51.6m |
| % growth | - | 1380 % | (64 %) | (74 %) | 97 % | (95 %) | - |
| EBITDA | (21.0m) | 12.0m | (24.2m) | (30.9m) | (21.1m) | (21.6m) | - |
| % EBITDA margin | (420 %) | 16 % | (91 %) | (454 %) | (157 %) | (3203 %) | - |
| Profit | (22.0m) | 13.0m | (25.7m) | (31.9m) | (23.8m) | (31.4m) | - |
| % profit margin | (440 %) | 18 % | (97 %) | (468 %) | (177 %) | (4658 %) | - |
| R&D budget | - | 55.0m | 44.6m | 29.2m | 27.5m | 13.9m | - |
| R&D % of revenue | - | 74 % | 168 % | 430 % | 205 % | 2068 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$20.3m | Series A | ||
€13.0m | Series B | ||
€10.0m | Series B | ||
| N/A | €26.9m | IPO | |
| N/A | €20.0m | Early VC | |
| N/A | €26.5m | Post IPO Equity | |
* | N/A | €17.7m | Post IPO Equity |
€6.0m | Post IPO Debt | ||
* | €6.0m | Post IPO Equity | |
* | €2.0m | Debt | |
| Total Funding | CAD92.2m | ||
Related Content
Recent News about Poxel
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.